A Phase II Study of DMP 115 to Assess Focal Liver Lesions
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00162058|
Recruitment Status : Completed
First Posted : September 13, 2005
Last Update Posted : August 18, 2011
|Condition or disease||Intervention/treatment||Phase|
|Liver Disease||Drug: Peflutren Lipid Microsphere Injectable Suspension||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Non-Randomized, Phase II Trial To Assess Focal Liver Lesion Detection Using Definity-Enhanced Ultrasound Imaging|
|Study Start Date :||March 2004|
|Actual Primary Completion Date :||April 2006|
|Actual Study Completion Date :||April 2006|
- The ratio of signal intensities obtained from unenhanced vs. contrast-enhanced ultrasound imaging of liver tissue and liver lesions will be calculated at the end of the study.
- The determination of the presence or absence of focal liver lesions during the Blinded Read and the Institutional Read of ultrasound images.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00162058
|Glasgow, Scotland, United Kingdom|
|Principal Investigator:||Edward L.S. Leen, MD||Consultant Radiologist, Royal Infirmary|